Global health agencies announced Wednesday that generic versions of a groundbreaking injectable drug to prevent HIV will be made available from 2027 at around $40 a year in more than 100 low and middle-income…
I don’t understand the wider picture: is Gilead likely to reduce the price in rich countries once it’s been licensed as a generic drug to poor countries (medical tourism, yay!). Or will they keep aggressively gouging?
I don’t understand the wider picture: is Gilead likely to reduce the price in rich countries once it’s been licensed as a generic drug to poor countries (medical tourism, yay!). Or will they keep aggressively gouging?
I guess it depends on when the patent expires?